The "Stop Counterfeiting in Manufactured Goods Act": What Every Lawyer Needs to Know (Hot Topic Briefing)
January 11, 2007
Intellectual Property Chair Sharon Barner will present at the Practising Law Institute’s (PLI) “Stop Counterfeiting in Manufactured Goods Act: What Every Lawyer Needs to Know” (Hot Topic Briefing) on Thursday, January 11, 2007 at 1:00 p.m. (EST). This program will examine the Stop Counterfeiting in Manufactured Goods Act, what it is designed to achieve, and its important provisions that every lawyer should know. Expert panelists will examine the growing problem of counterfeit products manufactured internationally and sold locally, cutting edge legal and technical tools to stop it, and whether you should and how best to get the government involved. In addition, this discussion will include the following issues:
- The realities of and solutions to dealing with “untouchable” defendants
- The examination of these issues from a defendant’s perspective — is it counterfeiting or just aggressive competition?
- Available remedies
Related Insights
June 6, 2025
Energy Current
House Bill 3809 Adds Obligations to Battery Energy Storage Lessees in Texas
On May 29, 2025, House Bill No. 3809 was signed into law by Texas Governor Greg Abbott. Born out of a crop of bills regulating renewable…
June 23, 2025
Events
Third Annual Transaction Solutions Symposium
Foley & Lardner is sponsoring the Third Annual Transaction Solutions Symposium — a premier conference focused on de-risking strategies that enhance deal execution and business outcomes. Rishi Sodhi will be speaking as part of the Tax Liability Insurance: Current Trends, Controversies and Claims panel.
June 5, 2025
Health Care Law Today
GLP-1 Compounded Medications Targeted by Connecticut Attorney General
On May 21, 2025, the Connecticut Office of the Attorney General released a statement and sent letters to Connecticut weight loss clinics, med spas, medical practices and other businesses regarding allegedly or potentially unfair and deceptive conduct relating to compounded GLP-1 medications.